| ￥3000 | |
| Z05097-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 50.37 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 52-65 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of BTN3A2 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »
BTN3A2 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | BTN3A2/BT3.2 butyrophilin mRNA expression by tumoral cells was previously identified as a prognostic factor in a small cohort of high grade serous epithelial ovarian cancer (HG-EOC).In conclusion, BT3.2 protein is a potential prognostic biomarker for the identification of HG-EOC patients with better outcome. In contrast, high CD206 /CD68 expression is associated with high risk of disease progression. |
| Synonyms | BT3.2; BTF3; BTF4; BT3.3; BTN3A2; FLJ40011; BTN3.2; CD277 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
